Abstract: IgG epitope and applications thereof as a target are provided. The IgG epitope is the CH1 domain of non-B cell-derived IgG, and there is N-glycosylated sialic acid modification at the Asn162 site of the domain. The realization of its antigen functions must depend on the sialylation of the site. The present invention further discloses the applications of the IgG epitope as a drug target in preparing drugs for diagnosis and/or treatment of epithelial tumors. In addition, our studies showed that this antigen depends on the sialylation of Asn162 site as a drug target, and the sialylation of this site must depend on sialyltransferase ST3GAL4, indicating that the enzyme can be used as a drug target for preparing tumor therapeutic drugs. Further, integrin ?4 is co-expressed and co-localized with IgG containing the epitope. IgG can be used as a marker for preparing drugs for the auxiliary detection of epithelial tumors.

Abstract: A method for selection of a calibration set and a validation set based on spectral similarity and modeling. The method includes: performing NIR spectrometry on original samples to obtain a spectral matrix of the original samples; randomly selecting m samples as an independent test set; calculating spectral similarity between each of the samples in the independent test set and each of the remaining samples in the original samples respectively to obtain g samples having the highest similarity to be written into the validation set; and calculating spectral similarity between each of the samples in the validation set and each of the remaining samples in the original samples respectively to obtain n samples having the highest similarity to be written into the calibration set. Based on the validation set and the calibration set selected through the method, an obtained model can predict unknown samples more accurately.

Abstract: The present invention provides a screening method for searching a component inhibiting or treating scleral thinning, and eyedrops that contain the active ingredient, and hence can inhibit excessive thinning of the sclera, and as a result, can treat a posterior segment eye disease associated with the scleral thinning. The problems are solved by eyedrops containing, as an active ingredient, a component capable of simultaneously inhibiting the PERK pathway and/or the ATF6 pathway. The problems are solved by a screening method for a component capable of simultaneously inhibiting the PERK pathway and/or the ATF6 pathway, including a step of contacting a candidate substance with an eye-derived cell, and a step of selecting the candidate substance using, as an indicator, influence on scleral thinning in the cell.

Abstract: A bolster beam is correspondingly connected to a connection base by means of a damping unit; the radial dimensions of an outer wall of an inner supporting member and an inner wall of an outer supporting member gradually decrease from one end to the other end in a vertical direction; one of the inner supporting member and the outer supporting member is connected to the connection base, and the other one is connected to the bolster beam; when in use, the inner supporting member and the outer supporting member tend to be close to each other, and since surfaces, close to each other, of the two are configured to be tapered, the two can-not be relatively separated; when getting closer to each other, the inner supporting member and the outer supporting member produce a compression action on an intermediate buffer member, and the intermediate buffer member is elastically deformable.

Abstract: A graft copolymer and a preparation method and use thereof. The method for preparing a graft copolymer includes: dissolving an N-ethyl-2-pyrrolidinone-substituted flavan-3-ol (EPSF) and a starch in a polar organic solvent, to obtain a raw material solution; and mixing the raw material solution with ascorbic acid and hydrogen peroxide to obtain a mixture, and subjecting the mixture to a grafting reaction, to obtain the graft copolymer.

Abstract: Provided herein are combination therapies for treating blood cancer, in particular, acute myeloid leukemia, by concurrently targeting Axl and BCL-2.

Abstract: IgG epitope and applications thereof as a target are provided. The IgG epitope is the CH1 domain of non-B cell-derived IgG, and there is N-glycosylated sialic acid modification at the Asn162 site of the domain. The realization of its antigen functions must depend on the sialylation of the site. The present invention further discloses the applications of the IgG epitope as a drug target in preparing drugs for diagnosis and/or treatment of epithelial tumors. In addition, our studies showed that this antigen depends on the sialylation of Asn162 site as a drug target, and the sialylation of this site must depend on sialyltransferase ST3GAL4, indicating that the enzyme can be used as a drug target for preparing tumor therapeutic drugs. Further, integrin ?4 is co-expressed and co-localized with IgG containing the epitope. IgG can be used as a marker for preparing drugs for the auxiliary detection of epithelial tumors.

Abstract: The present invention provides a novel chimeric antigen receptor, comprising an antigen-binding region, a transmembrane domain, a costimulatory domain, an intracellular signaling domain, and an additional signaling region. The additional signaling region consists of a ?c chain or an intracellular region thereof. The present invention also provides an engineered immune cell comprising the novel chimeric antigen receptor of the present invention and a pharmaceutical composition thereof, and use of the engineered immune cell/pharmaceutical composition for treating cancers.

Abstract: A model that closely resembles human excessive myopia can be prepared by mounting a minus lens (2) and a protector (4) to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention/suppression agent.

Abstract: Provided is a chimeric antigen receptor, comprising an antigen binding region, a transmembrane domain and an intracellular signaling region. The antigen binding region comprises an antibody specifically targeting CD7, and the intracellular signaling region consists of a co-stimulatory domain, a primary signal transduction domain, and a ?C chain or intracellular region thereof. Also provided are an engineered immune cell comprising the chimeric antigen receptor and a pharmaceutical composition thereof, and use of the engineered immune cell/pharmaceutical composition for treating cancers.

Abstract: Provided are an ROR1-targeting antibody, and a multispecific antibody, a chimeric antigen receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatment/prevention of diseases associated with ROR1 expression.

Abstract: The present invention provides a screening method for searching a component inhibiting the PERK pathway and/or the ATF6 pathway, and by obtaining, by the screening method, an active ingredient inhibiting myopia progression without impairing normal growth of the eyeballs (emmetropization) in children, provides eyedrops and a composition containing the active ingredient. The problems are solved by eyedrops for inhibiting myopia progression in children containing, as an active ingredient, an inhibitor of the PERK (PKR-like endoplasmic reticulum kinase) pathway and/or the ATF6 (activating transcription factor 6) pathway. The problems are solved by a screening method for an inhibitor of myopia progression in children, including a step of contacting a candidate substance with an eye-derived cell, and a step of selecting the candidate substance using, as an index, change in a protein and/or a gene of the signal transduction system of PERK and/or ATF6.

Abstract: Provided are an NKG2A-targeting antibody, and a multispecific antibody, a chimeric receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatment/prevention of diseases associated with NKG2A expression.

Abstract: The present invention provides a CD19-targeting humanized antibody, and a multispecific antibody, chimeric receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD19-targeting humanized antibody, and a use thereof in the diagnosis/treatment/prevention of diseases associated with CD19 expression.

Abstract: Provided is a chimeric antigen receptor, comprising a ligand-binding domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain. The co-stimulatory domain comprises an intracellular region of an NK-activated receptor or a ligand thereof. Also provided are an engineered immune cell comprising the chimeric antigen receptor and a use thereof in treatment of diseases, such as cancers, autoimmune diseases, and infections.

Abstract: The present invention provides a CD7-targeting humanized antibody, and a multispecific antibody, chimeric antigen receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD7-targeting humanized antibody, and a use thereof in the diagnosis/treatment/prevention of diseases associated with CD7 expression.

Abstract: Provided is an engineered immune cell. The cell expresses a chimeric antigen receptor comprising an antigen-binding region. The antigen-binding region comprises an anti-CD7 antibody, and the expression of endogenous CD7, at least one TCR/CD3 gene, and at least one MHC-II related gene is suppressed or silenced. Further provided is the use of the engineered immune cell in the treatment of diseases associated with CD7 expression.

Abstract: A device and a method for inhibiting thinning of a choroid. A choroidal thinning inhibiting device including a light source that emits violet light having a wavelength within a range from 360 nm to 400 nm, the choroidal thinning inhibiting device inhibiting thinning of a choroid by irradiation with the violet light. This device may further include a control mechanism that controls an irradiance and an irradiation time of the violet light, can be applied to ocular diseases selected from age-related macular degeneration, glaucoma, diabetic retinopathy, macular edema, eye strain, retinal vascular occlusion, triangle syndrome, central serous chorioretinopathy, retinitis pigmentosa, presbyopia, cataracts, and the like that are based on inadequate blood flow or reduced blood flow, and can be expected to prevent and treat such ocular diseases.

Abstract: A high-pressure fuel pump includes a drive shaft, and a vane pump and a plunger pump which are driven by the drive shaft. The vane pump is configured to supply pre-pressurized fuel to the plunger pump. The drive shaft includes a cam configured to drive a piston rod of the plunger pump such that the plunger pump alternately executes a fuel suction stroke and a fuel discharge stroke. The drive shaft further includes a shaft portion for driving a rotor of the vane pump. The vane pump is configured such that for each fuel suction stroke of the plunger pump the vane pump provides a fuel supply cycle that is advanced by a phase angle relative to the fuel suction stroke.